1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Atreca, Inc.
  6. Summary
    BCEL   US04965G1094

ATRECA, INC.

(BCEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/10/2022 05/11/2022 05/12/2022 05/13/2022 05/16/2022 Date
1.7(c) 1.61(c) 1.63(c) 1.65(c) 1.68(c) Last
241 970 457 380 230 277 378 420 178 767 Volume
-6.59% -5.29% +1.24% +1.23% +1.82% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -111 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,63x
Yield 2022 -
Sales 2023 10,0 M - -
Net income 2023 -130 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,68x
Yield 2023 -
Capitalization 64,8 M 64,8 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 6,48x
Nbr of Employees 134
Free-Float 79,9%
More Financials
Company
Atreca, Inc. is a biopharmaceutical company, which is engaged in developing antibody-based immunotherapeutics generated by its differentiated discovery platform. The Company's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. The Company's lead product... 
More about the company
Ratings of Atreca, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D
More Ratings
All news about ATRECA, INC.
05/11ATRECA, INC. Management's Discussion and Analysis of Financial Condition and Results o..
AQ
05/11Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments
GL
05/11Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments
AQ
05/11Atreca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/04ATRECA ANNOUNCES PUBLICATION IN PNAS : “Mobilization of Innate and Adaptive Antitumo..
GL
05/04Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumo..
CI
04/13ATRECA : Corporate Presentation April 2022
PU
04/08Atreca to Present at Upcoming Virtual Investor Conferences
GL
04/07ATRECA : Corporate Presentation January 2022
PU
04/05Atreca Strikes Licensing Deal With Zymeworks, Picks ATRC-301 as Next Clinical Candidate
MT
04/05ATRECA : 2022 R&D Day Presentation
PU
04/05ATRECA, INC. : Entry into a Material Definitive Agreement, Other Events (form 8-K)
AQ
04/05Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology
CI
04/05Atreca Announces Expansion of Preclinical Pipeline
AQ
03/23Atreca to Host Virtual R&D Day on Tuesday, April 5, 2022
AQ
More news
News in other languages on ATRECA, INC.
05/11Atreca, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/04Atreca, Inc. annonce une publication dans PNAS Mobilisation des réponses immunitaires a..
04/05Atreca conclut un accord de licence avec Zymeworks et choisit l'ATRC-301 comme prochain..
04/05Atreca, Inc. fait le point sur son portefeuille de produits précliniques en oncologie
03/08VENTE D'INITIÉS : Atreca
More news
Analyst Recommendations on ATRECA, INC.
More recommendations
Chart ATRECA, INC.
Duration : Period :
Atreca, Inc. Technical Analysis Chart | BCEL | US04965G1094 | MarketScreener
Technical analysis trends ATRECA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 1,68 $
Average target price 16,63 $
Spread / Average Target 890%
EPS Revisions
Managers and Directors
John A. Orwin President, Chief Executive Officer & Director
Herbert C. Cross Chief Financial Officer
Brian G. Atwood Chairman
Daniel Emerling Senior Vice President-Research
Jonathan Benjamin Vice President-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
ATRECA, INC.-44.55%65
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601